A pine bark extract just posted a surprising result in women with weakening bones: a key bone-breakdown marker fell, and pain scores improved. But the headline hides a catch that could change how you read it. In a 67-woman randomized trial, CTX-1 dropped within the Pycnogenol group, yet there was no significant difference versus placebo at any visit. A companion paper found better pain and vitality scores and a reassuring short-term safety profile. Here is what the dose, the data and the limitations really tell us.
This page is available in